JP2023540052A - 遺伝子構築物 - Google Patents

遺伝子構築物 Download PDF

Info

Publication number
JP2023540052A
JP2023540052A JP2023513671A JP2023513671A JP2023540052A JP 2023540052 A JP2023540052 A JP 2023540052A JP 2023513671 A JP2023513671 A JP 2023513671A JP 2023513671 A JP2023513671 A JP 2023513671A JP 2023540052 A JP2023540052 A JP 2023540052A
Authority
JP
Japan
Prior art keywords
target site
mir
mirna target
nucleic acid
mirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023540052A5 (enExample
Inventor
フラゴーソ，アナ・リタ・フレータス・マルチンス・デ・マトス
バラータ，ジョアン・ペドロ・タボルダ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Medicina Molecular Joao Lobo Antunes
Original Assignee
Instituto de Medicina Molecular Joao Lobo Antunes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Medicina Molecular Joao Lobo Antunes filed Critical Instituto de Medicina Molecular Joao Lobo Antunes
Publication of JP2023540052A publication Critical patent/JP2023540052A/ja
Publication of JP2023540052A5 publication Critical patent/JP2023540052A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023513671A 2020-08-27 2021-08-25 遺伝子構築物 Pending JP2023540052A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2013466.4 2020-08-27
GBGB2013466.4A GB202013466D0 (en) 2020-08-27 2020-08-27 Genetic construct
PCT/PT2021/050028 WO2022045912A1 (en) 2020-08-27 2021-08-25 Genetic construct

Publications (2)

Publication Number Publication Date
JP2023540052A true JP2023540052A (ja) 2023-09-21
JP2023540052A5 JP2023540052A5 (enExample) 2024-08-07

Family

ID=72749679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513671A Pending JP2023540052A (ja) 2020-08-27 2021-08-25 遺伝子構築物

Country Status (5)

Country Link
US (1) US20230313229A1 (enExample)
EP (1) EP4204572A1 (enExample)
JP (1) JP2023540052A (enExample)
GB (1) GB202013466D0 (enExample)
WO (1) WO2022045912A1 (enExample)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032954A2 (en) * 2000-10-20 2002-04-25 Leadd B.V. Phosphorylation modifications of apoptin
JP2005506386A (ja) * 2001-10-22 2005-03-03 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 腫瘍特異的細胞傷害性を誘導するための方法および組成物
WO2012012739A2 (en) * 2010-07-22 2012-01-26 President And Fellows Of Harvard College Multiple input biologic classifier circuits for cells
JP2015526410A (ja) * 2012-06-26 2015-09-10 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2016108333A1 (en) * 2014-12-31 2016-07-07 Korea Institute Of Radiological & Medical Sciences Method for screening agent against cancer metastasis using bax/complex-i conjugate
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
US20200040338A1 (en) * 2018-08-01 2020-02-06 Massachusetts Institute Of Technology Rna-based regulatory technologies for mirna sensors
WO2020091958A1 (en) * 2018-11-01 2020-05-07 Onconetics Pharmaceuticals, Inc. Multi-component vector systems, methods of making, and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1661912A1 (en) * 2004-11-29 2006-05-31 Xigen S.A. Fusion protein comprising a BH3-domain of a BH3-only protein
CN104017827A (zh) * 2014-04-04 2014-09-03 天津医科大学总医院 一种慢病毒质粒表达载体及其构建方法和应用
CN108676097B (zh) * 2018-05-24 2020-01-14 北京肽和生物科技有限公司 一种靶向肿瘤细胞的嵌合肽或嵌合蛋白及其应用

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032954A2 (en) * 2000-10-20 2002-04-25 Leadd B.V. Phosphorylation modifications of apoptin
JP2005506386A (ja) * 2001-10-22 2005-03-03 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 腫瘍特異的細胞傷害性を誘導するための方法および組成物
WO2012012739A2 (en) * 2010-07-22 2012-01-26 President And Fellows Of Harvard College Multiple input biologic classifier circuits for cells
JP2015526410A (ja) * 2012-06-26 2015-09-10 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
WO2016108333A1 (en) * 2014-12-31 2016-07-07 Korea Institute Of Radiological & Medical Sciences Method for screening agent against cancer metastasis using bax/complex-i conjugate
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
US20200040338A1 (en) * 2018-08-01 2020-02-06 Massachusetts Institute Of Technology Rna-based regulatory technologies for mirna sensors
WO2020091958A1 (en) * 2018-11-01 2020-05-07 Onconetics Pharmaceuticals, Inc. Multi-component vector systems, methods of making, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. KAMATA、他: "Live Cell Monitoring of hiPSC Generation and Differentiation Using Differential Expression of Endoge", PLOS ONE, vol. 5(7), JPN7025002773, 28 July 2010 (2010-07-28), pages 11834, ISSN: 0005625724 *

Also Published As

Publication number Publication date
WO2022045912A1 (en) 2022-03-03
US20230313229A1 (en) 2023-10-05
GB202013466D0 (en) 2020-10-14
EP4204572A1 (en) 2023-07-05

Similar Documents

Publication Publication Date Title
Chen et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma
Wang et al. Synthetic circular multi-miR sponge simultaneously inhibits miR-21 and miR-93 in esophageal carcinoma
US9163261B2 (en) Adeno-associated virus 2/8—micro RNA-101 therapy for liver cancer
CN107267625B (zh) lncRNA作为生物标志物在肝癌诊疗中的用途
US20180237775A1 (en) Antisense oligonucleotides and uses thereof
Wu et al. From super-enhancer non-coding RNA to immune checkpoint: frameworks to functions
CA2946407A1 (en) Multiple targeted rnai for the treatment of cancers
JP2025084803A (ja) 標的化されたＩｎ ｖｉｖｏエピジェネティック抑制を介した持続性鎮痛剤
WO2017192662A2 (en) Methods for identifying treatment targets based on multiomics data
WO2022018667A1 (en) Combination therapies using cdk2 and cdc25a inhibitors
JP2019162111A (ja) 福山型筋ジストロフィー治療用アンチセンス核酸
WO2007084954A2 (en) Selective inhibition of ig20 splice variants to treat cancers
EP3134528A1 (en) Multiple targeted rnai for the treatment of cancers
Peng et al. CircFAT1 promotes lung adenocarcinoma progression by sequestering miR-7 from repressing IRS2-ERK-mediated CCND1 expression
JP2019503204A (ja) アプタマーによるポリアデニル化の調節を通じての遺伝子発現制御
JP2010533212A (ja) マイクロｒｎａ分子を含む抗癌組成物
US20160220599A1 (en) Novel lincrna and interfering nucleic acid molecules, compositions and methods and uses thereof for regulating angiogenesis and related conditions
US20200147118A1 (en) Compositions and methods for detection, risk assessment and treatment of diabetes, obesity, and inflammation
US20230313229A1 (en) Genetic Construct
US11566247B2 (en) Modulation of alternative MDM2 splicing
CN105779576B (zh) 人tnfrsf12a基因的用途及其相关药物
WO2023150702A2 (en) Compositions and methods for treatment of connective tissue disorders
US20230016983A1 (en) Antisense oligonucleotides and thier use for the treatment of cancer
CN105803053B (zh) 人rbm17基因的用途及其相关药物
US20180119150A1 (en) Methods for Treating Acute Myeloid Leukemia and Nanoparticle Complexes of miR-22 Utilized Therein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240730

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260529